Pfizer Has Had Cécile Geiger as Interim CFO Since August Amid Leadership Transition
Key Facts
Pfizer’s available announcement did not confirm Cécile Geiger’s appointment as permanent chief financial officer on November 3, 2026; it documented her temporary assumption of the role during the company’s finance leadership transition. Pfizer announced on June 18, 2026, that Dave Denton would leave the CFO role on August 15 and that Geiger would take over on an interim basis starting August 16. This timeline frames the change as a transition arrangement announced months earlier, not a new permanent appointment on the date of the news. The company said Denton and Geiger would work together to ensure a smooth transition. According to Pfizer’s statement, Denton would leave the company for a career opportunity in the consumer goods sector outside the pharmaceutical industry.
Pfizer said Denton would leave his role on August 15, while Geiger would begin her interim responsibilities the following day, August 16. The announcement dated June 18 set out these dates as part of the CFO transition plan. The company’s filing with the Securities and Exchange Commission said Denton’s departure was not related to Pfizer’s financial or operating results. It also said the departure was not connected to disagreements over financial, operating or accounting policies or reporting practices. This sets out the company’s stated explanation for the departure, while the search for a successor was part of the arrangement accompanying Geiger’s interim appointment.
Before taking on the interim role, Geiger was senior vice president of finance for Pfizer’s Global Biopharmaceuticals Business. The company said that, as of its June 2026 announcement, she had more than two decades of experience at Pfizer, spanning strategic portfolios, research and development, and multiple geographies. Pfizer also cited her involvement in integrating Seagen into the company in 2024. The company’s SEC filing shows that she joined Pfizer in 2005 and had held her then-current role since 2022. Before that, from 2020 to 2022, she served as vice president of finance for research and development and the Business Operations group.
Chief Executive Officer Albert Bourla expressed confidence in Geiger’s ability to lead the finance organization, linking her role to executing the company’s strategy and serving patients and shareholders. Pfizer’s executive leadership page describes Geiger as chief financial officer and executive vice president, and says she has more than 25 years of global financial leadership experience in the pharmaceutical industry. The page describes her role and experience, while the announcement specifying the start of her interim appointment dates to June 2026. Her background in finance, research and development, and business operations provides professional context for overseeing the finance function during the transition. But the June announcement itself described her appointment as interim while the company searched for a successor.
In its second-quarter 2026 results, Pfizer reported revenue of $15.0 billion, with year-over-year operational growth of 1%. At the same time, the company raised the midpoint of its fiscal 2026 revenue guidance by $500 million, to a range of $60.5 billion to $62.5 billion. These figures provide financial context for the company during the period when the CFO transition was announced, showing operational revenue growth and a revision to the annual outlook. The transition announcement did not link these results to Denton’s departure; Pfizer’s SEC filing said the departure was not related to financial or operating results. This context also does not establish that a new permanent appointment was made on November 3.
Pfizer shares closed at $30.67 on November 2, 2026, according to EL7 daily data. That figure is for the session before the date of the news and does not represent a close on November 3. Reuters, meanwhile, reported that the stock fell 3.1% to $25.1 in early trading on June 18, when Denton’s departure and Geiger’s interim appointment were announced. The agency quoted a Scotiabank analyst saying the CFO’s departure raised concerns about the 2026 outlook, succession plans and the timing of the change, as the company prepared to enter the obesity drug market. That move and reaction relate to the June session, while the November 2 data do not include a documented daily range or link the stock’s close to a new development in finance leadership.
Pfizer had scheduled its webcast on third-quarter 2026 results for November 3 at 10:00 a.m. Eastern time. The company listed the event among its quarterly corporate performance events for the third quarter. The webcast date falls on the same date as the news and provides a near-term occasion to present the period’s results. The available transition announcement records Geiger’s interim appointment starting August 16 and does not confirm a new permanent appointment on November 3. As of the scheduled webcast, these remain the announced facts about the third-quarter results date and the transition timeline.